What insurance policy changes affect HCPCS J1100?

There are 18 tracked policy changes affecting HCPCS J1100, including updates from Missouri Medicaid (MO HealthNet), Arkansas Blue Cross Blue Shield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J1100?

Payers that have issued tracked updates for HCPCS J1100 include: Missouri Medicaid (MO HealthNet), Arkansas Blue Cross Blue Shield, Aetna, Florida Blue, Texas Medicaid.

How do I get notified when HCPCS J1100 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J1100. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J1100?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J1100 — Injection, dexamethasone sodium phosphate, 1 mg: Insurance Policy Changes

J1100 Insurance Policy Changes

HCPCS J1100 is officially defined as "Injection, dexamethasone sodium phosphate, 1 mg." HCPCS J1100 is referenced in 18 tracked payer policy changes from Missouri Medicaid (MO HealthNet), Arkansas Blue Cross Blue Shield, and 3 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J1100 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Rozanolixizumab-noli (Rystiggo) (CPB 1035, reviewed 2026-08-11)

Aetna·Effective Aug 11, 2026

Aetna has established a new medical policy (CPB 1035) for Rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker for generalized myasthenia gravis. The policy requires precertification before treatment, restricts prescribing to neurologists, and establishes specific clinical criteria including antibody positivity, MGFA classification II-IV, MG-ADL score ≥5, and documented failure of at least two immunosuppressive therapies or one immunosuppressive plus IVIG over 12 months. Billing teams must implement prior authorization workflows and track the new HCPCS code J9333.

J1100 Insurance Policy Changes

Changes to Preferred Biosimilar Medications Effective October 1, 2026

Policy Criteria Change

Rozanolixizumab-noli (Rystiggo) (CPB 1035, reviewed 2026-08-11)

Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)

Belantamab Mafodotin-blmf (Blenrep) (CPB 0981, reviewed 2026-02-06)

Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)

Anifrolumab-fnia (Saphnelo) (CPB 0997, reviewed 2026-06-05)

Isatuximab-irfc (Sarclisa) (CPB 0969, reviewed 2026-03-02)

Elotuzumab (Empliciti) (CPB 0899, reviewed 2026-03-02)

Carfilzomib (Kyprolis) (CPB 0845, reviewed 2026-03-02)

Medicare Part B Step Therapy Product Updates

Benralizumab (Fasenra) (CPB 0925, reviewed 2025-12-23)

Updates to Prior Authorization for Services and Clinician-Administered Drug Benefits for HTW/HTW Plus

Siltuximab (Sylvant) (CPB 0884, reviewed 2026-06-03)

Remestemcel-L-rknd (Ryoncil) (CPB 1077, reviewed 2026-05-27)

Emapalumab-lzsg (Gamifant) (CPB 0948, reviewed 2025-12-08)

Vitiligo (CPB 0422, reviewed 2026-07-16)

HHSC to Host a Minimum Data Set Webinar about PDPM Aug. 19